Activatable interleukin 12 polypeptides and methods of use thereof
The disclosure features fusion proteins that are conditionally active variants of IL-12. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
1. A pharmaceutical composition comprising at least one of each of:
a) a human interleukin 12 (IL-12) polypeptide comprising an IL-12 subunit polypeptide selected from IL-12p35 and IL-12p40;
b) an IL-12 blocking moiety, wherein the IL-12 blocking moiety comprises a ligand-binding domain or fragment of a cognate receptor for the IL-12 polypeptide, or an antibody or antigen-binding fragment of an antibody that binds the IL-12 polypeptide;
c) a protease-cleavable polypeptide linker; and
d) a half-life extension element wherein the half-life extension element is human serum albumin, an antigen-binding polypeptide that binds human serum albumin, or an immunoglobulin Fc;
wherein the IL-12 subunit polypeptide and the IL-12 blocking moiety are operably linked by the protease-cleavable polypeptide linker, the IL-12 polypeptide has attenuated IL-12-receptor activating activity at least about 10 fold less than the IL-12-receptor activating activity of the polypeptide that comprises the IL-12 polypeptide that is produced by cleavage of the protease-cleavable polypeptide linker, and wherein the IL-12 receptor activating activity is assessed using a using a HEK Blue reporter cell assay, with equal amounts on a mole basis of the IL-12 polypeptide and the pharmaceutical composition.
2. The pharmaceutical composition of claim 1 , wherein the half-life extension element is operably linked to IL-12p35.
3. The pharmaceutical composition of claim 1 , wherein the half-life extension element is operably linked to IL-12p40.
4. The pharmaceutical composition of claim 1 , comprising a first polypeptide comprising at least one of each of: a) a human interleukin 12 (IL-12) subunit polypeptide selected from IL-12p35 and IL-12p40; b) an IL-12 blocking moiety; and c) a protease-cleavable polypeptide linker, wherein the IL-12 subunit polypeptide and the IL-12 blocking moiety are operably linked by the protease-cleavable polypeptide linker.
5. The pharmaceutical composition of claim 1 , comprising a first polypeptide and a second polypeptide, wherein the first polypeptide comprises at least one of each of: a) a human interleukin 12 (IL-12) subunit polypeptide selected from IL-12p35 and IL-12p40; b) an IL-12 blocking moiety; and c) a protease-cleavable polypeptide linker, wherein the IL-12 subunit polypeptide and the IL-12 blocking moiety are operably linked by the protease-cleavable polypeptide linker; and wherein the second polypeptide comprises a human interleukin 12 (IL-12) subunit polypeptide selected from IL-12p35 and IL-12p40.
6. The pharmaceutical composition of claim 1 , further comprising a tumor-specific antigen binding peptide.
7. The pharmaceutical composition of claim 1 , comprising a human IL-12p35 subunit polypeptide and a human IL-12p40 subunit polypeptide.
8. The pharmaceutical composition of claim 1 , wherein the protease-cleavable polypeptide linker comprises at least one sequence that is capable of being cleaved by a protease selected from the group consisting of a kallikrein, thrombin, chymase, carboxypeptidase A, cathepsin G, cathepsin L, an elastase, PR-3, granzyme M, a calpain, a matrix metalloproteinase (MMP), a fibroblast activation protein (FAP), an ADAM metalloproteinase, a plasminogen activator, a cathepsin, a caspase, a tryptase, and a tumor cell surface protease.
9. The pharmaceutical composition of claim 1 , wherein IL-12 blocking moiety inhibits activation of the IL-12 receptor by the human IL-12 polypeptide.
10. The pharmaceutical composition of claim 1 , wherein the antibody fragment that binds to IL-12 is a single domain antibody, Fab or scFv.
11. The pharmaceutical composition of claim 1 , wherein the IL-12 polypeptide comprises a naturally-occurring IL-12 polypeptide sequence or a functional fragment thereof.
12. The pharmaceutical composition of claim 1 , wherein the protease cleavable polypeptide linker comprises a sequence that is cleaved by cathepsin selected from the group consisting of cathepsin B, cathepsin C, cathepsin D, cathepsin E, cathepsin K, cathepsin L, and cathepsin G.
13. The pharmaceutical composition of claim 1 , wherein the protease cleavable polypeptide linker comprises a sequence that is cleaved by a matrix metalloprotease (MMP) is selected from the group consisting of MMP1, MMP2, MMP3, MMP8, MMP9, MMP10, MMP11, MMP12, MMP13, and MMP14.
14. The pharmaceutical composition of claim 1 , wherein the serum half-life of the IL-12 polypeptide that is produced by cleavage of the protease-cleavable polypeptide linker is comparable to the half-life of naturally occurring IL-12.
15. The pharmaceutical composition of claim 1 , wherein the IL-12 polypeptide that is produced by cleavage if the protease-cleavable polypeptide linker does not comprise the half-life extension element or IL-12 blocking moiety.
16. The pharmaceutical composition of claim 1 , wherein the cognate receptor for the IL-12 is IL-12R beta 1 (IL-12Rβ1) or IL12R beta 2 (IL-12Rβ2).